These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32026428)

  • 1. Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study.
    Hahn B; Stanford RH; Goolsby Hunter A; Essoi B; White J; Ray R
    Pulm Ther; 2019 Jun; 5(1):69-80. PubMed ID: 32026428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study.
    Ray R; Hahn B; Stanford RH; White J; Essoi B; Hunter AG
    Pulm Ther; 2019 Dec; 5(2):191-200. PubMed ID: 32026409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study.
    Hahn B; Stanford RH; Hunter AG; White J; Essoi B; Ray R
    Pulm Ther; 2019 Dec; 5(2):179-190. PubMed ID: 32026410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD.
    Strange C; Walker V; DePietro M; Tong J; Kurlander J; Carlyle M; Millette LA; Wittbrodt E
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1377-1388. PubMed ID: 31303751
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
    J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
    [No Abstract]   [Full Text] [Related]  

  • 6. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.
    Lane DC; Stemkowski S; Stanford RH; Tao Z
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1165-1172. PubMed ID: 30362922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting.
    Stephenson JJ; Wertz D; Gu T; Patel J; Dalal AA
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1947-1959. PubMed ID: 28740375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β
    Requena G; Banks V; Czira A; Wood R; Tritton T; Wild R; Compton C; Duarte M; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1781-1795. PubMed ID: 35983168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Transitions in Chronic Obstructive Pulmonary Disease: Retrospective Analyses of US and UK Healthcare Databases.
    Bloom CI; Montonen J; Jöns O; Garry EM; Bhatt SP
    Pulm Ther; 2022 Mar; 8(1):75-93. PubMed ID: 35015269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS.
    Buhl R; Dreher M; Mattiucci-Guehlke M; Emerson-Stadler R; Eckhardt S; Taube C; Vogelmeier CF
    Adv Ther; 2023 Jul; 40(7):3263-3278. PubMed ID: 37256536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COPD symptom burden: impact on health care resource utilization, and work and activity impairment.
    Ding B; Small M; Bergström G; Holmgren U
    Int J Chron Obstruct Pulmon Dis; 2017; 12():677-689. PubMed ID: 28260874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
    van Geffen WH; Tan DJ; Walters JA; Walters EH
    Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
    Bengtson LGS; DePietro M; McPheeters J; Fox KM
    Ther Adv Respir Dis; 2018; 12():1753466618772750. PubMed ID: 29737943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England.
    Sansbury LB; Lipson DA; Bains C; Anley GA; Rothnie KJ; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():415-426. PubMed ID: 35264848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overuse of long-acting β
    Brunton SA; Hogarth DK
    Postgrad Med; 2023 Nov; 135(8):784-802. PubMed ID: 38032494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan.
    Yamada H; Hida N; Hizawa N
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3141-3147. PubMed ID: 30349222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS; Landis SH; Wurst K; Le H
    Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
    Oba Y; Keeney E; Ghatehorde N; Dias S
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.